Johnson & Johnson plans to separate its orthopedics business into a standalone company named DePuy Synthes, with the split expected to take 18 to 24 months.
The orthopedics business designs and sells medical devices and implants used to treat injuries or disorders of the bones, joints and spine: hip and knee replacements, implants for facial reconstruction, instruments for spinal fusion and the like. The unit generated about $9.2B in sales last year, roughly 10% of J&J’s total.
Although that is a sizable share of the portfolio, the ortho unit is capital-intensive and slower-growing than J&J’s other medtech or pharma areas, which is why it is being spun out into its own focused company. The split lets each side concentrate on higher-growth, higher-margin areas: medtech at DePuy Synthes and pharma at J&J. The most recent separation before this one was Kenvue, the consumer health business, in 2023.
Why split
The growth gap is the argument. Across J&J’s divisions, the ortho unit grows at about 2.5% a year, against roughly 6% for J&J MedTech overall and about 8% for pharma, according to Orthoworld data.
Splitting a slower-growth unit can lift J&J’s margins and capital efficiency, and the new company and team get a new identity to run M&A, portfolio clean-ups and commercial focus specifically in joints, trauma and spine. Medtech has seen similar moves recently: the GE HealthCare spin, Medtronic’s diabetes split plans and ZimVie from Zimmer Biomet. Pure-plays, companies focusing on one area, often trade on clearer comps, meaning analysts can directly compare them with similar companies such as Stryker and Zimmer Biomet, and on operating KPIs. These splits are complex, involving systems, supply chain and salesforce separation, and the orthopedics market depends heavily on hospital budgets.
On 2024 estimates, DePuy Synthes sits second among orthopedics market leaders at $9.2B in revenue, behind Stryker at $21.0B and ahead of Zimmer Biomet at $7.4B. The broader global medical devices market, which includes ortho, is forecast to grow from roughly $540B in 2024 to about $885B by 2032, per Fortune Business Insights.
What to watch
As an independent company, DePuy can dedicate leadership, capital and strategy solely to orthopedics rather than competing for resources within J&J’s broader portfolio, while J&J focuses more on its own projects. These kinds of spin-offs tend to perform well when the separated company operates in a mature but innovation-driven market such as medtech.
An open question is whether this spin-off triggers a new wave of medtech restructurings, with other diversified giants like Medtronic or Siemens Healthineers carving out slower-growth units next.
The past integrations of DePuy in 1998 and Synthes in 2012 created a giant in orthopedics, and unwinding it now will require flawless execution. Any slip in robotics or pricing strategy could weaken the spin-off’s promise. On the other side, DePuy Synthes gains its own independence to pursue AI, specifically in implant design and surgical robotics. With players like NVIDIA partnering across medtech, the next leap could blend hardware with intelligent, data-driven surgical systems.